FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308369510> ?p ?o ?g. }

• W4308369510 abstract "Waning protection against emerging SARS-CoV-2 variants by pre-existing antibodies elicited because of current vaccination or natural infection is a global concern. Whether this is due to the waning of immunity to SARS-COV-2 remains unclear.We aimed to investigate the dynamics of antibody isotype responses amongst vaccinated naïve (VN) and naturally infected (NI) individuals.We followed up antibody levels in COVID-19 messenger RNA (mRNA)-vaccinated subjects without prior infection (VN, n = 100) in two phases: phase-I (P-I) at ~ 1.4 and phase-II (P-II) at ~ 5.3 months. Antibody levels were compared with those of unvaccinated and naturally infected subjects (NI, n = 40) at ~ 1.7 (P-1) and 5.2 (P-II) months post-infection. Neutralizing antibodies (NTAb), anti-S-RBD-IgG, -IgM and anti-S-IgA isotypes were measured.The VN group elicited significantly greater antibody responses (P < 0.001) than the NI group at P-I, except for IgM. In the VN group, a significant waning in antibody response was observed in all isotypes. There was about an ~ 4-fold decline in NTAb levels (P < 0.001), anti-S-RBD-IgG (~5-fold, P < 0.001), anti-S-RBD-IgM (~6-fold, P < 0.001) and anti-S1-IgA (2-fold, P < 0.001). In the NI group, a significant but less steady decline was notable in S-RBD-IgM (~2-fold, P < 0.001), and a much smaller but significant difference in NTAb (<2-fold, P < 0.001) anti-S-RBD IgG (<2-fold, P = 0.005). Unlike the VN group, the NI group mounted a lasting anti-S1-IgA response with no significant decline. Anti-S1-IgA, which were ~ 3-fold higher in VN subjects compared with NI in P-1 (P < 0.001), dropped to almost the same levels, with no significant difference observed between the two groups in P-II.Whereas double-dose mRNA vaccination boosted antibody levels, vaccinated individuals' 'boost' was relatively short-lived." @default.
• W4308369510 created "2022-11-11" @default.
• W4308369510 creator A5014846631 @default.
• W4308369510 creator A5015050252 @default.
• W4308369510 creator A5016520050 @default.
• W4308369510 creator A5017050680 @default.
• W4308369510 creator A5028129003 @default.
• W4308369510 creator A5029565170 @default.
• W4308369510 creator A5045545412 @default.
• W4308369510 creator A5051168138 @default.
• W4308369510 creator A5056039813 @default.
• W4308369510 creator A5056668005 @default.
• W4308369510 creator A5076585377 @default.
• W4308369510 creator A5085431202 @default.
• W4308369510 creator A5087611083 @default.
• W4308369510 date "2022-11-07" @default.
• W4308369510 modified "2023-10-15" @default.
• W4308369510 title "Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection" @default.
• W4308369510 cites W2109471081 @default.
• W4308369510 cites W3012320055 @default.
• W4308369510 cites W3082342835 @default.
• W4308369510 cites W3092050672 @default.
• W4308369510 cites W3096525230 @default.
• W4308369510 cites W3111255098 @default.
• W4308369510 cites W3111459703 @default.
• W4308369510 cites W3112389805 @default.
• W4308369510 cites W3131938123 @default.
• W4308369510 cites W3137782989 @default.
• W4308369510 cites W3157162195 @default.
• W4308369510 cites W3163785571 @default.
• W4308369510 cites W3164094536 @default.
• W4308369510 cites W3167129132 @default.
• W4308369510 cites W3168825791 @default.
• W4308369510 cites W3175112548 @default.
• W4308369510 cites W3177903130 @default.
• W4308369510 cites W3178962125 @default.
• W4308369510 cites W3189614603 @default.
• W4308369510 cites W3197801192 @default.
• W4308369510 cites W3200630639 @default.
• W4308369510 cites W3200840478 @default.
• W4308369510 cites W3208413321 @default.
• W4308369510 cites W3212382349 @default.
• W4308369510 cites W4200275675 @default.
• W4308369510 cites W4205483821 @default.
• W4308369510 cites W4206390478 @default.
• W4308369510 cites W4207066590 @default.
• W4308369510 cites W4210870949 @default.
• W4308369510 cites W4220678484 @default.
• W4308369510 cites W4221068248 @default.
• W4308369510 cites W4225695315 @default.
• W4308369510 cites W4225854071 @default.
• W4308369510 cites W4281990949 @default.
• W4308369510 cites W4308573582 @default.
• W4308369510 doi "https://doi.org/10.1093/jtm/taac130" @default.
• W4308369510 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36342115" @default.
• W4308369510 hasPublicationYear "2022" @default.
• W4308369510 type Work @default.
• W4308369510 citedByCount "2" @default.
• W4308369510 countsByYear W43083695102023 @default.
• W4308369510 crossrefType "journal-article" @default.
• W4308369510 hasAuthorship W4308369510A5014846631 @default.
• W4308369510 hasAuthorship W4308369510A5015050252 @default.
• W4308369510 hasAuthorship W4308369510A5016520050 @default.
• W4308369510 hasAuthorship W4308369510A5017050680 @default.
• W4308369510 hasAuthorship W4308369510A5028129003 @default.
• W4308369510 hasAuthorship W4308369510A5029565170 @default.
• W4308369510 hasAuthorship W4308369510A5045545412 @default.
• W4308369510 hasAuthorship W4308369510A5051168138 @default.
• W4308369510 hasAuthorship W4308369510A5056039813 @default.
• W4308369510 hasAuthorship W4308369510A5056668005 @default.
• W4308369510 hasAuthorship W4308369510A5076585377 @default.
• W4308369510 hasAuthorship W4308369510A5085431202 @default.
• W4308369510 hasAuthorship W4308369510A5087611083 @default.
• W4308369510 hasBestOaLocation W43083695101 @default.
• W4308369510 hasConcept C126322002 @default.
• W4308369510 hasConcept C159047783 @default.
• W4308369510 hasConcept C159654299 @default.
• W4308369510 hasConcept C203014093 @default.
• W4308369510 hasConcept C22070199 @default.
• W4308369510 hasConcept C2777991845 @default.
• W4308369510 hasConcept C2779134260 @default.
• W4308369510 hasConcept C2779261636 @default.
• W4308369510 hasConcept C2779341262 @default.
• W4308369510 hasConcept C2780898057 @default.
• W4308369510 hasConcept C3008058167 @default.
• W4308369510 hasConcept C524204448 @default.
• W4308369510 hasConcept C542903549 @default.
• W4308369510 hasConcept C71924100 @default.
• W4308369510 hasConcept C8891405 @default.
• W4308369510 hasConceptScore W4308369510C126322002 @default.
• W4308369510 hasConceptScore W4308369510C159047783 @default.
• W4308369510 hasConceptScore W4308369510C159654299 @default.
• W4308369510 hasConceptScore W4308369510C203014093 @default.
• W4308369510 hasConceptScore W4308369510C22070199 @default.
• W4308369510 hasConceptScore W4308369510C2777991845 @default.
• W4308369510 hasConceptScore W4308369510C2779134260 @default.
• W4308369510 hasConceptScore W4308369510C2779261636 @default.
• W4308369510 hasConceptScore W4308369510C2779341262 @default.
• W4308369510 hasConceptScore W4308369510C2780898057 @default.
• W4308369510 hasConceptScore W4308369510C3008058167 @default.

• next